Old Web
English
Sign In
Acemap
>
authorDetail
>
Guopan Yu
Guopan Yu
University of Texas MD Anderson Cancer Center
Bruton's tyrosine kinase
Cancer research
Medicine
Wild type
Tyrosine kinase
6
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy
2018
Blood
Weiguo Zhang
Guopan Yu
Hongying Zhang
Charlie Ly
Bin Yuan
Vivian Ruvolo
Sujan Piya
Seemana Bhattacharya
Qi Zhang
Gautam Borthakur
Venkata Lokesh Battula
Marina Konopleva
William G. Rice
Michael Andreeff
Show All
Source
Cite
Save
Citations (0)
Abstract 25: CG′806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3
2017
Clinical Cancer Research
Weiguo Zhang
Hongying Zhang
Andrea Local
William G. Rice
Charlie J. Ly
Guopan Yu
Stephen B. Howell
Michael Andreeff
Show All
Source
Cite
Save
Citations (1)
CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status
2017
Blood
Guopan Yu
Weiguo Zhang
Charlie Ly
Hongying Zhang
William G. Rice
Michael Andreeff
Show All
Source
Cite
Save
Citations (0)
1